SCHEMBL19728640

SCHEMBL19728640

CCOC(=O)c1cn(-c2cc(N)c(F)cc2COC(C)=O)c2cc(F)c(F)cc2c1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 3/20 0.43
HPGD P15428 3/20 0.43
HSD17B10 Q99714 3/20 0.43
PIM1 P11309 1/20 0.42
IRAK1 P51617 1/20 0.42
CAMK2B Q13554 1/20 0.42
CAMK2G Q13555 1/20 0.42
CAMK2D Q13557 1/20 0.42
PIM3 Q86V86 1/20 0.42
STAT3 P40763 2/20 0.42
ROCK2 O75116 1/20 0.41
CDK1 P06493 1/20 0.41
PRKACA P17612 1/20 0.41
CDK2 P24941 1/20 0.41
CSNK1D P48730 1/20 0.41
GSK3A P49840 1/20 0.41
CDK5 Q00535 1/20 0.41
PRKCD Q05655 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19728795 0.90 KMT2A (0.41) KMT2AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL19728798 0.88 STAT3 (0.55) KMT2AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL19728365 0.88 KDM4E (0.50) KMT2AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL7005217 0.87 KMT2A (0.56) KMT2AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL20912578 0.86 STAT3 (0.49) KMT2AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL19728792 0.86 KDM4E (0.47) KMT2AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL19728789 0.86 KDM4E (0.47) KMT2AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL19728785 0.86 KDM4E (0.45) KMT2AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL19728641 0.86 ALDH1A1 (0.44) KMT2AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL19729388 0.85 ALDH1A1 (0.50) KMT2AALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190276407-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2019-09-12 US disclosed
US-20190276407-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2019-09-12 US disclosed
EP-3473616-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF Wakunaga Pharmaceutical Co., Ltd. (JP) 2019-04-24 EP disclosed
WO-2017217441-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF 湧永製薬株式会社 2017-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276407-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF CTR9, PYCR1, ACAD9 KMT2A 2161/4885ALDH1A1 960/4885KDM4E 2371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.